Navigation Links
Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Antigenics Pharmaceuticals is to start its Phase III cancer vaccine trial against Melanoma which is a type of skin cancer. Oncophage is the new skin cancer vaccine developed by Antigenics.// The vaccine trial of Oncophage which was conducted in 322 patients failed to meet the required statistically significance results compared to prolongation in survival and the vaccine was not shown to have any better results compared to other cancer treatments.

But, earlier studies with Oncophage showed a group of patients with the least-advanced severity of melanoma in the trial lived 20.9 months on Oncophage compared to 12.8 months for those patients taking standard drugs, the company said. The difference had not yet reached statistical significance and the trial is continuing.

Antigenics is to start a Phase III study next year to test its vaccine on a more responsive group, patients with Stage IV M1a patients. Though, the trial is to cost the company more than $12 million the scientists of the company are confident over the results.

Needham & Co. analyst Mark Monane in a research note called the data "encouraging" but only "hypothesis-generating rather than hypothesis-confirming, that we believe that any intensive reading into the data at this stage may be premature."
'"/>




Page: 1

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
4. Top Pharmaceuticals Influence Doctors Prescriptions
5. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
6. Personalized Medicine and Innovative Pharmaceuticals
7. Pravastatin Launched by Watson Pharmaceuticals
8. Tata Industries picks up stake in Indigene Pharmaceuticals
9. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
10. OPPI Opposes Draft National Pharmaceuticals Policy
11. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: